Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of ...
Grants include research funding in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), Duchenne muscular ...
Jada Bafus told Page Six that she and the actress quickly came to realize it was a case of “two triggered mothers” having a ...
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...
Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated ...
The life Chris and Mariesa built together in Cincinnati, where they moved for work 13 years ago, is a testament to their love ...
US Weekly on MSN
Hilary Swank ‘Took the Time to Learn’ About Make-A-Wish Mom’s Terminally Ill Kids After Altercation
The mother of two terminally ill boys has opened up about making peace with Oscar winner Hilary Swank following an alleged ...
Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy December ...
The Scottish Medical Consortium has approved the use of givinostat to treat children aged six and older who are still able to ...
Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.
Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.
The Scottish Medical Consortium has approved the use of givinostat to treat children aged six and older who are still able to walk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback